
    
      PRIMARY OBJECTIVES:

      I. To evaluate preliminary efficacy of lorcaserin to improve balance decrements in patients
      with chronic chemotherapy-induced peripheral neuropathy (CIPN).

      SECONDARY OBJECTIVES:

      I. To evaluate patient reported outcomes (PROs) after a one time dose of lorcaserin in
      patients with chronic CIPN.

      OUTLINE:

      Patients receive lorcaserin orally (PO) on day 1.

      After completion of study treatment, patients are followed for 4 weeks.
    
  